Navigation Links
Vivo Ventures Closes $375 Million 7th Fund to Invest in Healthcare in the U.S. and Greater China
Date:1/3/2012

PALO ALTO, Calif., Jan. 3, 2012 /PRNewswire/ -- Vivo Ventures, a healthcare investment firm with offices in Palo Alto, California, Shanghai, and Chengdu, China, announced the final closing of Vivo Ventures VII ("Vivo VII") at $375 million, which brings the firm's total funds under management to more than $1 billion.

Vivo plans to invest the capital primarily in later development stage pharmaceutical and medical device companies in the U.S. and in revenue stage healthcare companies in greater China.  As an early entrant to the Chinese healthcare market, Vivo plans to continue assisting companies in both countries in their efforts to forge cross-border partnerships, enabling companies to acquire new products and expand the market for their existing products.  Vivo also intends to continue its successful strategies of building companies from scratch, identifying later stage products with a high probability of FDA approval, and investing directly in public companies.

Vivo's recent IPOs and exits include Sagent (IPO, Nasdaq), China Kanghui (IPO, NYSE), Vicept (acquired by Allergan), Bioform (acquired by Merz), as well as investments in Avanir Pharmaceuticals (Nasdaq), Acura Pharmaceuticals (Nasdaq), Lee's Pharm (HKEx), and Achillion Pharmaceuticals (Nasdaq).

The managing partners of Vivo VII are Drs. Frank Kung, Albert Cha, Edgar Engleman, Chen Yu, and James Zhao. Investors in the Vivo VII include pension funds, funds of funds, university endowments, foundations, financial institutions, and family offices. In addition to limited partners that participated in Vivo's earlier funds, Vivo VII added a number of new institutional investors from the U.S., Europe, and Asia.

About Vivo Ventures

Founded in 1996, Vivo Ventures is a healthcare investment firm focused on investing in and building high quality companies in the U.S. and China.  With more than $1 billion under management, Vivo employs a unique multi-pronged strategy of identifying and working with companies with promising later development stage products in the U.S. and revenue stage companies in China.   Vivo Ventures (http://www.vivoventures.com) has offices in Palo Alto, California, Shanghai, China, and Chengdu, China. 

 

 


'/>"/>
SOURCE Vivo Ventures, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Global Diagnostic Imaging Companies M&A, Joint Ventures, R&D Pipeline, and Strategies
2. PharmaSecure, an Innovator in Pharmaceutical Serialization, Closes $3.9M Investment by Eric Schmidts Innovation Endeavors, Gray Ghost Ventures, Healthtech Capital and the TEEC Angel Fund
3. USRBC President Ed Verona Lauds GE Announcement on Energy and Healthcare Joint Ventures in Russia
4. Allegra® and Survivor Winner Danni Boatwright Want to Hear About Your "Allergy Adventures"
5. Global Health Ventures August 4th Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
6. Global Health Ventures to Present Live, Online at RetailInvestorConferences.com on August 4th
7. PharmaVentures Engaged by Avexa to Assist in the Out-licensing of Apricitabine
8. Vivo Ventures Announces Promotions of Dr. Chen Yu and Dr. James Zhao to Managing Partner
9. XDATA Retains Adapt IP Ventures to Market Patents and Technology for Automated 3D Ultrasound Imaging System
10. Aethlon Medical to Present the Aethlon ADAPT™ System at C21 BioVentures™ Life Sciences Partnering Conference
11. JumpStart Ventures Invests in Cleveland-based SPR Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... 2017 IRIDEX Corporation (Nasdaq: IRIX ... for the fourth quarter and 2016 after the close ... management team will host a corresponding conference call beginning ... Investors interested in listening to the conference call ... callers or (703) 326-3030 for international callers, using conference ...
(Date:2/22/2017)... , Feb. 22, 2017 Summary ... infarction partnering deals and agreements entered into by ... full report: http://www.reportlinker.com/p03605670-summary/view-report.html Description The ... understanding and access to partnering deals and agreements ... - Trends in partnering deals ...
(Date:2/22/2017)... , Feb. 22, 2017 Merrimack Pharmaceuticals, Inc. ... will host its Fourth Quarter 2016 investor conference call and ... The call will cover an update on ... quarter and full year 2016 financial results. A press release ... be issued the morning of Wednesday, March 1. Investors and ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... February 22, 2017 , ... ... in recent years. The technology is so cutting edge, in fact, the U.S. ... for stem cell procedures. However, successful patient outcomes in certain clinical stem cell ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... its certification exam and eligibility requirements effective with the April 2017 testing period. ... 1995. , “The Care Manager Certified (CMC) exam is periodically re-calibrated to ...
(Date:2/22/2017)... Dallas, TX (PRWEB) , ... ... ... HCC Risk Adjustment solution leverages advanced data analytics to accurately understand each ... ensure proper reimbursement for a given population. This new solution helps transform ...
(Date:2/22/2017)... ... ... Doctors on Liens is continuing its steady expansion of medical specialties throughout ... North Valley Eye Medical Group in Mission Hills . Eye injuries and vision ... cases. These injuries have a major impact on the quality of life of ...
(Date:2/22/2017)... ... February 22, 2017 , ... Using the power of the ... simple online checklist. Over a period of just 24 months, thousands of individuals interested ... online checklist called T.A.D. , “The internet is not getting quieter. In fact it’s ...
Breaking Medicine News(10 mins):